As previously reported, Morgan Stanley downgraded Dentsply Sirona (XRAY) to Equal Weight from Overweight with a price target of $14, down from $21, citing sluggish innovation, share loss dynamics, tariff risk and uncertainty, and a challenging macro and dental demand backdrop. While the stock is “clearly cheap” after being the worst performer in the group in 2024 and being down 21% year-to-date, the firm views the broader outlook as uncertain given the potential tariff exposure and macro risk.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Dentsply Sirona downgraded to Equal Weight from Overweight at Morgan Stanley
- Dentsply Sirona price target lowered to $16 from $19 at BofA
- Dentsply Sirona files automatic mixed securities shelf
- Dentsply Sirona appoints David Ferguson as SVP, global business unit leader
- Microsoft, Intel upgraded: Wall Street’s top analyst calls